#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15462	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2165	711.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1743	1743	T	843	T,C	777,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15462	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2165	711.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1477	1477	C	962	C,T	887,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15462	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2165	711.0	0	HET	.	.	.	A69G	.	69	69	A	362	362	A	843	A,G	444,350	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28180	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3675	764.8	0	.	n	.	0	C1176T	SNP	1176	1176	C	1533	1533	T	863	T,C,A	805,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28180	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3675	764.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1694	1694	A	902	A	849	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28180	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3675	764.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2328	2328	C	871	C	806	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28180	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3675	764.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2402	2402	A	878	A	833	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28180	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3675	764.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2954	2954	C	842	C,A	791,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	539	2206	folP	852	852	99.88	folP.l15.c4.ctg.1	1531	143.3	0	.	p	.	0	E151K	NONSYN	451	453	GAA	768	770	AAA	182;180;179	A,G;A;A	168,1;168;169	.	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	539	2206	folP	852	852	99.88	folP.l15.c4.ctg.1	1531	143.3	1	SNP	p	R228S	1	.	.	682	684	AGC	999	1001	AGC	251;248;247	A;G;C	234;228;225	folP.WHO_X_01360c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5896	gyrA	2751	2751	99.89	gyrA.l6.c17.ctg.1	3283	178.7	0	.	p	.	0	K261del	DEL	781	781	A	1038	1038	A	165	A	157	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5896	gyrA	2751	2751	99.89	gyrA.l6.c17.ctg.1	3283	178.7	1	SNP	p	S91F	0	.	.	271	273	TCC	528	530	TCC	201;196;198	T;C;C	190;187;189	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5896	gyrA	2751	2751	99.89	gyrA.l6.c17.ctg.1	3283	178.7	1	SNP	p	D95N	0	.	.	283	285	GAC	540	542	GAC	208;210;208	G;A;C	197;200;198	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5896	gyrA	2751	2751	99.89	gyrA.l6.c17.ctg.1	3283	178.7	1	SNP	p	D95G	0	.	.	283	285	GAC	540	542	GAC	208;210;208	G;A;C	197;200;198	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1776	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1373	128.9	1	SNP	p	G45D	0	.	.	133	135	GGC	514	516	GGC	236;236;238	G;G;C	220;218;220	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	882	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1101	79.8	0	.	n	.	0	A197.	DEL	197	197	A	643	643	A	199	A	187	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5376	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2894	185.0	1	SNP	p	D86N	0	.	.	256	258	GAC	568	570	GAC	212;212;213	G;A;C	196;197;196	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5376	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2894	185.0	1	SNP	p	S87R	0	.	.	259	261	AGT	571	573	AGT	213;213;213	A;G;T	195;195;193	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5376	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2894	185.0	1	SNP	p	S87I	0	.	.	259	261	AGT	571	573	AGT	213;213;213	A;G;T	195;195;193	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5376	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2894	185.0	1	SNP	p	S87W	0	.	.	259	261	AGT	571	573	AGT	213;213;213	A;G;T	195;195;193	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5376	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2894	185.0	1	SNP	p	S88P	0	.	.	262	264	TCC	574	576	TCC	211;212;214	T;C;C	191;193;194	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4850	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2526	191.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1525	1527	GGC	246;243;240	G;G;C	230;225;221	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4408	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2403	182.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1261	1263	GCA	252;254;257	G,T;C;A	234,1;241;246	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4408	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2403	182.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1264	1266	ATC	259;261;263	A;T;C	246;246;249	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4408	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2403	182.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1276	1278	GTG	257;258;263	G;T;G	245;246;249	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4408	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2403	182.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1276	1278	GTG	257;258;263	G;T;G	245;246;249	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4408	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2403	182.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1780	1782	ACC	237;237;236	A;C;C	215;222;222	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4408	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2403	182.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1834	1836	GCG	202;200;203	G;C,G;G	180;162,1;174	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4408	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2403	182.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1834	1836	GCG	202;200;203	G;C,G;G	180;162,1;174	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4408	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2403	182.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1957	1959	GGC	195;191;193	G;G;C,T	183;176;180,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4408	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2403	182.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1966	1968	GGC	201;196;195	G;G;C	183;182;181	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4408	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2403	182.7	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1984	1986	CTG	187;186;184	C,G;T;G	149,6;136;143	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6238	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	2989	207.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1534	1536	CCG	265;265;264	C;C;G	241;244;240	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2280	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1900	119.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	611	611	C	149	C	137	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2938	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1493	195.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	413	415	GAA	250;251;250	G;A;A	232;236;233	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2938	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1493	195.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	701	703	GAT	238;236;239	G;A;T,C	221;220;223,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2938	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1493	195.7	0	.	p	.	0	P175L	NONSYN	523	525	CCA	824	826	TTA	218;218;218	T;T;A	206;206;205	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2938	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1493	195.7	0	.	p	.	0	D212N	NONSYN	634	636	GAT	935	937	AAT	228;229;229	A;A;T	214;215;211	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2938	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1493	195.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	953	955	GTC	228;228;225	G,T;T;C	214,1;214;213	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2938	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1493	195.7	0	.	p	.	0	F222S	NONSYN	664	666	TTT	965	967	TCT	231;230;231	T;C;T	217;217;217	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2938	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1493	195.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1283	1285	GCA	214;219;219	G;C,T;A	202;207,1;207	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2938	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1493	195.7	1	SNP	p	G120K	1	.	.	358	360	AAG	659	661	AAG	255;257;257	A;A;G	244;243;245	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2938	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1493	195.7	1	SNP	p	A121D	1	.	.	361	363	GAC	662	664	GAC	260;257;257	G;A;C,G	247;243;243,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2938	porB1b	1047	1047	99.04	porB1b.l15.c17.ctg.1	1493	195.7	1	SNP	p	D121N	0	.	.	361	363	GAC	662	664	GAC	260;257;257	G;A;C,G	247;243;243,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	11560	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4908	235.0	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2027	2029	AAT	260;256;254	A;A;T	245;242;240	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1200	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	884	134.3	1	SNP	p	V57M	1	.	.	169	171	ATG	469	471	ATG	257;257;255	A,T;T;G	247,1;248;246	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
